Compare · CI vs DGX
CI vs DGX
Side-by-side comparison of The Cigna Group (CI) and Quest Diagnostics Incorporated (DGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and DGX operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $78.96B, about 3.0x DGX ($26.40B).
- CI has been more active in the news (5 items in the past 4 weeks vs 3 for DGX).
- Both have 25 recent analyst ratings on file.
- Company
- The Cigna Group
- Quest Diagnostics Incorporated
- Price
- -
- -
- Market cap
- $78.96B
- $26.40B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Latest CI
- SEC Form 8-K filed by The Cigna Group
- The Cigna Group's Third Quarter 2026 Earnings Release Details
- Cigna Healthcare Introduces Health Sense To Connect Guidance, Benefits and Clinical Support Around Each Person, Improving Affordability and Outcomes
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- The Cigna Group Hosts 2026 Investor Day; Introduces "Lead to One" to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities
- Is Volunteering Good for Your Health? New Research From The Cigna Group Finds a Strong Connection
- Evercore ISI initiated coverage on The Cigna Group with a new price target
- The Cigna Group to Host Investor Day on September 30
- Officer Neville Everett sold $175,259 worth of shares (617 units at $284.05) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 5,053 units (SEC Form 4)
- Officer Evanko Brian C was granted 3,113 shares, increasing direct ownership by 8% to 41,030 units (SEC Form 4)
Latest DGX
- SEC Form 8-K filed by Quest Diagnostics Incorporated
- SEC Form 4 filed by Director Wentworth Timothy C
- Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
- Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
- Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
- Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
- Apple Health app Users to be Able to Order Labs from Quest Diagnostics
- CEO and President Davis J. E. sold $2,427,200 worth of shares (10,000 units at $242.72) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 122,423 units (SEC Form 4)
- SVP & General Counsel Prevoznik Michael E exercised 22,677 shares at a strike of $112.17, sold $5,513,083 worth of shares (22,677 units at $243.11) as part of a pre-agreed trading plan and gifted 1,000 shares, decreasing direct ownership by 3% to 36,557 units (SEC Form 4)
- Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference